Yao Lin

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study.

Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study.

Journal: Annals of surgical oncology

Published: December 23, 2025

PANoptosis-triggering GA-based biomimetic nano-prodrug remodels the tumor microenvironment to enhance antitumor immunity.

PANoptosis-triggering GA-based biomimetic nano-prodrug remodels the tumor microenvironment to enhance antitumor immunity.

Journal: Biomaterials

Published: October 13, 2025

Prognostic utility of the newstage system integrating tumor regression grade and lymph node status for locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.

Prognostic utility of the newstage system integrating tumor regression grade and lymph node status for locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.

Journal: International journal of surgery (London, England)

Published: August 08, 2025

Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.

Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.

Journal: Future oncology (London, England)

Published: July 12, 2025

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites.

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 09, 2025

Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.

Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.

Journal: World journal of surgical oncology

Published: May 18, 2025

Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.

Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 10, 2025

Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study.

Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: September 16, 2024

Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.

Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.

Journal: Annals of surgical oncology

Published: April 08, 2024

ESRP1-driven alternative splicing of CLSTN1 inhibits the metastasis of gastric cancer.

ESRP1-driven alternative splicing of CLSTN1 inhibits the metastasis of gastric cancer.

Journal: Cell death discovery

Published: October 04, 2023

Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.

Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.

Journal: Cancer science

Published: May 06, 2023

Metformin promotes cGAS/STING signaling pathway activation by blocking AKT phosphorylation in gastric cancer.

Metformin promotes cGAS/STING signaling pathway activation by blocking AKT phosphorylation in gastric cancer.

Journal: Heliyon

Published: February 07, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026